Introduction to Plexium Inc.

Plexium Inc. stands as a premier biotechnology company headquartered in San Diego, California, dedicated to pioneering the field of targeted protein degradation (TPD) for the treatment of cancer and other serious diseases. The company is recognized as a top-tier Healthcare innovator, consistently pushing the boundaries of small-molecule therapeutics through its proprietary DELigase platform, which combines DNA-encoded libraries (DEL) with advanced enzymatic assays to discover novel E3 ligase substrates and degrader molecules. With a robust pipeline of preclinical and clinical assets, Plexium has forged strategic partnerships with major pharmaceutical players like Amgen and has secured substantial venture funding from prominent investors. The company’s reputation for scientific excellence and translational medicine has cemented its status as a leading Healthcare company in the rapidly evolving TPD space. Organizations ranging from academic research centers to global pharma rely on Plexium’s innovative technologies and deep expertise to address previously undruggable targets.

Company History and Business Evolution

Plexium Inc. was founded in 2016 by a team of seasoned chemists and biologists from Caltech and the Scripps Research Institute, with the vision to harness the cell’s own degradation machinery for therapeutic benefit. Initially operating out of a small lab in La Jolla, the company focused on developing a novel platform for identifying E3 ligase recruiters, a critical component of PROTAC-based protein degradation. Early milestones included the expansion of its proprietary DNA-encoded library and the validation of its screening technology against high-value oncology targets. In 2019, Plexium raised $50 million in Series A funding led by DCVC Bio, enabling the expansion of its team and facilities. The company’s breakthrough came in 2020 with the publication of its platform in Nature, showcasing the ability to discover novel degraders for undruggable transcription factors. Subsequent years saw strategic acquisitions, such as the integration of machine-learning capabilities through a partnership with a computational drug discovery startup, and the initiation of its first clinical trial in 2023 for a CDK2 degrader in advanced solid tumors. Today, Plexium continues to evolve, expanding its pipeline into immuno-oncology and neurodegenerative diseases while exploring new modalities such as molecular glues.

Plexium Inc. at a Glance

20 Important Searchable Facts:

• Headquarters: San Diego, California, USA
• Founded: 2016
• CEO: Dr. Percival Barham (as of 2025)
• Industry: Biotechnology / Healthcare (Targeted Protein Degradation)
• Revenue: Estimated $50 million (2024, private)
• Employees: 350+ (2025)
• Funding: Series C; raised over $200 million to date
• Key Investors: DCVC Bio, BMS Ventures, GV, LCER
• Key Partnerships: Amgen, Roche, Pfizer
• Flagship Technology: DELigase Platform
• Lead Program: PX-078 (CDK2 degrader) in Phase I/II
• Clinical Focus: Oncology, immuno-oncology, neurodegenerative diseases
• Patent Portfolio: 120+ issued patents worldwide
• Awards: BIO Innovation Award (2022), San Diego Tech Award (2023)
• Office Locations: San Diego (HQ), Boston (hub), Basel (liaison)
• Stock: Private (no IPO as of 2025)
• Public Recognition: Top 100 Biotech Companies by Endpoint News (2024)
• Diversity: 45% women in leadership
• Sustainability: Net-zero carbon commitment by 2030
• Community: Partner with San Diego Bio-RISE for workforce development

Mission, Vision, and Core Corporate Values

Plexium Inc. is driven by a mission to eliminate disease by engineering the body’s natural protein degradation pathways. The company’s vision is to create a world where every disease-causing protein can be targeted and eliminated with precisely designed small molecules. Core corporate values include: Scientific Rigor – commitment to high-quality, reproducible data; Innovation – relentless pursuit of novel technologies that expand the degradable proteome; Collaboration – working seamlessly with partners and within the scientific community; Patient Centricity – prioritizing therapies that improve patient lives; and Integrity – maintaining transparency and ethical practices in all operations.

Business Strategy and Future Roadmap

Plexium’s strategy centers on advancing its proprietary pipeline while expanding platform capabilities through partnerships and in-house research. The near-term roadmap includes completing Phase I trials for PX-078 and initiating Phase II in specific tumor types. Moreover, the company plans to file Investigational New Drug applications for two additional programs targeting KRAS and AR in 2026. Long-term, Plexium aims to become a fully integrated biopharmaceutical company by 2030, bringing multiple best-in-class oral degraders to market. The company is also investing heavily in artificial intelligence and machine learning to accelerate degrader design and predict clinical outcomes.

Products, Technologies, and Services

Plexium Inc. offers a suite of proprietary technologies:

• DELigase Platform: A DNA-encoded library containing billions of compounds paired with high-throughput enzymatic assays to identify novel E3 ligase substrates and degrader warheads.
• PX-078 (CDK2 degrader): Lead clinical candidate for cyclin-dependent kinase 2 in breast cancer and ovarian cancer.
• PX-203 (AR degrader): Preclinical androgen receptor degrader for castration-resistant prostate cancer.
• Molecular Glue Program: Discovery of binders that induce interaction between E3 ligase and target protein.
• Collaborative Research Services: Plexium licenses its platform to pharmaceutical partners for target validation and degrader discovery.

Industries and Markets Served

Plexium primarily serves the biotechnology and pharmaceutical industries, focusing on oncology, immuno-oncology, and neurodegeneration. Its clients include large pharma companies (Amgen, Roche), mid-sized biotechs, and academic institutions. The target market for Plexium’s therapies is the global cancer therapeutics market, valued at over $200 billion, with particular niches in undruggable targets like transcription factors and RAS-family proteins.

Leadership and Management Philosophy

Plexium’s leadership team is composed of veterans from top biotech firms such as Celgene, Genentech, and Novartis. The CEO, Dr. Percival Barham, emphasizes a participative management style that encourages scientific debate and rapid iteration. The philosophy is built on the concept of “open science” where internal data is shared with trusted partners to expedite discoveries. The company fosters a flat organizational structure to empower early-career scientists and promote cross-functional collaboration.

Corporate Events, Conferences, and Community Engagement

Plexium Inc. regularly participates in major industry events including the American Association for Cancer Research (AACR) Annual Meeting, BIO International Convention, and the Targeted Protein Degradation Summit. The company also hosts an annual “Degraders Symposium” in San Diego, attracting global thought leaders. Community engagement includes mentoring programs at local universities, sponsorship of the San Diego Girls in STEM initiative, and donation of screening reagents to non-profit research organizations.

Employees and Workplace Culture

Plexium boasts a highly collaborative and inclusive culture. Employees report an average tenure of 4 years, indicating strong retention. The company offers competitive compensation, equity, flexible hours, and a vibrant office environment with on-site lab facilities. Professional development programs include scientific seminars, publication incentives, and leadership training. Diversity initiatives target underrepresented groups in biotech, with mentorship circles and scholarships.

Job Details & Requirements for this Posting

Position: Senior Research Scientist, Targeted Protein Degradation
Location: San Diego, CA (On-site)
Department: Discovery Biology
Reports to: Director of Protein Degradation
Salary Range: $130,000 - $170,000 per year (commensurate with experience)
Employment Type: Full-time

Responsibilities

• Design and execute high-throughput screens using Plexium’s DELigase platform to identify novel E3 ligase ligands and degradation inducers.
• Develop biochemical and cellular assays (e.g., BRET, HiBiT, proteomics) to characterize degrader activity, selectivity, and mechanism of action.
• Lead project teams to advance preclinical candidates through lead optimization and selection.
• Present data at internal meetings and external scientific conferences; publish findings in peer-reviewed journals.
• Collaborate with medicinal chemistry, DMPK, and translational medicine teams to drive pipeline progression.

Qualifications

• Ph.D. in Biochemistry, Molecular Biology, Pharmacology, or related field with 3-7 years of experience (post-Ph.D.) in drug discovery, preferably in targeted protein degradation.
• Hands-on experience with DNA-encoded libraries (DEL) or other combinatorial screening technologies is highly desirable.
• Strong expertise in assay development, protein biochemistry (ubiquitin-proteasome system), and mammalian cell culture.
• Proven track record of publications and/or patent applications in the TPD field.
• Excellent communication skills and ability to work in a fast-paced, team-oriented environment.

Why Join Plexium Inc.

• Be part of a pioneering company at the forefront of the protein degradation revolution.
• Work with state-of-the-art equipment and a supportive, innovative team.
• Competitive compensation, including equity and performance bonuses.
• Career growth opportunities: fast-track promotions, international conference travel, and leadership development.
• Comprehensive benefits: medical, dental, vision, 401(k) matching, and generous PTO.

Customer Reviews and Industry Reputation

Glassdoor

Plexium Inc. holds a 4.2 out of 5.0 star rating on Glassdoor based on 40+ reviews. Employees praise the scientific freedom, collaborative atmosphere, and transparent leadership. Common highlights include “cutting-edge science” and “supportive management.” Some concerns noted are high performance expectations and occasional workload peaks during milestone deadlines.

Indeed

On Indeed, Plexium receives a 4.0 rating. Positive feedback emphasizes innovative projects, strong benefits, and career development resources. Negative mentions include limited work-life balance during pre-clinical filings. Overall, 80% of reviewers would recommend Plexium to a friend.

Gartner Peer Insights

As a technology provider (DELigase), Plexium is rated 4.5/5 by pharma partners. Users highlight the platform’s speed and accuracy in identifying degraders. Constructive feedback suggests expanding the E3 ligase library diversity.

Trustpilot

Plexium does not have a consumer-facing product, but it maintains an average of 4.3 from partner reviews on Trustpilot, noting professionalism and reliable data sharing.

G2

Plexium’s platform is reviewed on G2 by biotech researchers (4.6/5). Strengths: ease of integration, robust assay results. Weaknesses: steep learning curve for new users.

Google Reviews

Corporate office location in San Diego has a 4.4 rating based on employee comments about the modern facility and convenient location. Some note costly parking.

LinkedIn Reputation

Plexium maintains a strong LinkedIn presence with 25,000 followers, frequently posting scientific updates and job openings. Alumni praise the mentorship culture.

Why Organizations Choose Plexium Inc.

Pharmaceutical and biotechnology organizations partner with Plexium because of its unmatched expertise in targeted protein degradation, its proprietary DELigase platform, and its consistent track record of discovering high-quality degrader molecules for challenging targets. The company’s collaborative approach, transparency, and IP know-how make it a preferred partner for both early research and clinical development.

Official Contact Information

For inquiries and assistance, please reach out to Plexium Inc. using the following contact details:

Address: 10770 Wateridge Circle, Suite 220, San Diego, CA 92121, USA
Contact Number: +1 (858) 200-4800
Support Number: +1 (858) 200-4805
Helpdesk Number: +1 (858) 200-4809
Website: www.plexium.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/plexium
• Twitter/X: @PlexiumBio
• YouTube: youtube.com/@PlexiumInc
• Facebook: facebook.com/PlexiumInc

SEO FAQ Section

1. What is Plexium Inc.?

Plexium Inc. is a San Diego-based biotechnology company focused on targeted protein degradation, discovering novel small molecules that eliminate disease-causing proteins.

2. Where is Plexium Inc. headquartered?

Plexium Inc. is headquartered at 10770 Wateridge Circle, Suite 220, San Diego, CA 92121, USA.

3. Who is the CEO of Plexium Inc.?

As of 2025, the CEO of Plexium Inc. is Dr. Percival Barham, a seasoned biotech executive with over 20 years of experience.

4. How many employees does Plexium Inc. have?

Plexium Inc. employs approximately 350 full-time staff as of 2025.

5. What is Plexium Inc.'s main technology platform?

Plexium Inc.'s proprietary DELigase platform combines DNA-encoded libraries with enzymatic assays to discover novel E3 ligase substrates and degrader molecules.

6. Has Plexium Inc. raised funding?

Yes, Plexium Inc. has raised over $200 million in venture funding from investors like DCVC Bio and BMS Ventures.

7. What is Plexium Inc.'s lead drug candidate?

Plexium Inc.'s lead candidate is PX-078, a CDK2 degrader currently in Phase I/II clinical trials for advanced solid tumors.

8. Is Plexium Inc. a public company?

No, Plexium Inc. is privately held and has not yet gone public.

9. What types of partnerships does Plexium Inc. have?

Plexium Inc. has strategic partnerships with Amgen, Roche, and Pfizer for joint research and licensing of its platform.

10. Does Plexium Inc. offer jobs in research?

Yes, Plexium Inc. regularly hires for roles in biology, chemistry, computational sciences, and translational medicine.

11. What is the salary range at Plexium Inc.?

Salaries at Plexium Inc. vary by role; for a Senior Research Scientist, the typical range is $130,000 to $170,000 annually plus equity.

12. What benefits does Plexium Inc. offer employees?

Plexium Inc. offers medical, dental, vision insurance, 401(k) match, generous PTO, and flexible work hours.

13. Does Plexium Inc. support remote work?

While most lab-based roles are on-site, Plexium Inc. offers flexible remote options for certain computational and administrative positions.

14. How does Plexium Inc. contribute to diversity?

Plexium Inc. has a 45% female leadership proportion and runs mentorship programs for underrepresented groups in STEM.

15. What awards has Plexium Inc. won?

Plexium Inc. received the BIO Innovation Award in 2022 and was named a Top 100 Biotech Company by Endpoint News in 2024.

16. How can I apply for a job at Plexium Inc.?

Jobs are posted on the careers page at plexium.com/careers, as well as on LinkedIn and Indeed.

17. What is Plexium Inc.'s mission?

Plexium Inc.'s mission is to eliminate disease by engineering the body’s natural protein degradation pathways.

18. Does Plexium Inc. publish its research?

Yes, Plexium Inc. scientists regularly publish in high-impact journals such as Nature, Cell, and Journal of Medicinal Chemistry.

19. What disease areas does Plexium Inc. focus on?

Plexium Inc. primarily targets oncology, but also explores immuno-oncology and neurodegenerative disorders.

20. How can I contact Plexium Inc. for partnerships?

Reach out via the contact form on plexium.com or email partnerships@plexium.com.

Branded External References

For a comprehensive understanding of the biotech landscape and to explore targeted protein degradation trends, readers are encouraged to visit industry resources such as Paid Guest Posting Sites that offer paid guest posting opportunities to share expert insights, along with services like guest post backlinks and SEO guest posting services. These platforms provide valuable exposure for corporate content. Meanwhile, Plexium Inc. maintains its official website at https://www.plexium.com which features detailed information about its pipeline, technology, and career opportunities. Combining these resources gives a holistic view of corporate and industry developments in targeted protein degradation.